Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cosyntropin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.74 |
| ▸ | MC4R | P32245 | 3/20 | 0.72 |
| ▸ | MC5R | P33032 | 2/20 | 0.72 |
| ▸ | MC3R | P41968 | 2/20 | 0.72 |
| ▸ | MC1R | Q01726 | 2/20 | 0.72 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
| ▸ | NMBR | P28336 | 1/20 | 0.59 |
| ▸ | GRPR | P30550 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cosyntropin SCHEMBL720535 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29948667 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL33366 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL27555834 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL522396 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649201 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL25356191 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL31252906 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649167 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL563374 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20240307505-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | ZHANG, JING (CN) | 2024-09-19 | — | — | US | claimed |
| US-20240002469-A1 | CD164 FUSION AND USES THEREOF | JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2024-01-04 | — | — | US | claimed |
| EP-4292605-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | Zhang, Jing (CN) | 2023-12-20 | — | — | EP | claimed |
| EP-4244260-A1 | CD164 FUSION AND USES THEREOF | Jiangsu Cell Tech Medical Research Institute Co., Ltd. (CN) | 2023-09-20 | — | — | EP | claimed |
| EP-3509573-B1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC (TW) | 2023-05-24 | — | — | EP | claimed |
| WO-2022206716-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | 张菁 | 2022-10-06 | — | — | WO | claimed |
| CN-115137809-A | Medicine containing adrenocorticotropic hormone and its derivative and its use | 张菁 | 2022-10-04 | — | — | CN | claimed |
| EP-4049651-A1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | Kindeva Drug Delivery L.P. (US) | 2022-08-31 | — | — | EP | claimed |
| CN-108135837-B | Zinc composition for coating microneedle arrays | 3M创新有限公司 | 2022-05-31 | — | — | CN | claimed |
| WO-2022100555-A1 | CD164 FUSION AND USES THEREOF | JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2022-05-19 | — | — | WO | claimed |
| WO-2022099695-A1 | CD164 FUSION AND USES THEREOF | JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2022-05-19 | — | — | WO | claimed |
| US-20220133627-A1 | Stable Therapeutic Formulations | ALZA CORP (US) | 2022-05-05 | — | — | US | claimed |
| EP-3359129-B1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | KINDEVA DRUG DELIVERY LP (US) | 2022-02-23 | — | — | EP | claimed |
| US-12616736-B2 | Method of diagnosis of adrenal insufficiency | SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4721785-A2 | DRUG INJECTION APPARATUS, SYSTEMS AND METHODS | SOLUtion Medical, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-3960134-A1 | IMPLANTABLE THERAPEUTIC DEVICE | ForSight Vision4, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3359129-B1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | KINDEVA DRUG DELIVERY LP (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022027110-A1 | COMBINATION OF TRIDECACTIDE AND METHENKEPHALIN FOR TREATING CONDITIONS INVOLVING CYTOKINE STORM | BOSNALIJEK, FARMACEUTSKA I HEMIJSKA INDUSTRIJA, DIONIČKO DRUŠTVO (BA) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616736-B2 | Method of diagnosis of adrenal insufficiency | CRH, MC2R, NR3C2 | C5AR1 394/4885MC4R 271/4885MC5R 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.